Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)
Clinical trial NCT06360575 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06360575
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-07-20
- Primary completion
- 2022-11-15
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.